ARTICLE | Clinical News

Tresiba insulin degludec regulatory update

October 5, 2015 7:00 AM UTC

FDA approved NDAs from Novo Nordisk for Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart to improve glycemic control in adult Type I and II diabetics. Novo Nordisk said Tresiba would be available to specialists this quarter, with a full commercial launch planned for 1Q16; a launch timeline has not been set for Ryzodeg. Tresiba will be available in the FlexTouch pen. The company said prices would not be available “for a few weeks” (see BioCentury, April 13). ...